How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?

FAQ Library published on July 18, 2016
Download Transcript Download Audio
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Hi and welcome to Managing Myeloma. My name is Dr. Sagar Lonial, and I am a Professor at the Winship Cancer Institute of Emory University in Atlanta, Georgia. Another great question that I am often asked is, “How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?” And I think some of that is going to be driven by a lot of the data that is emerging, both at the ASCO meeting in 2016 as well as at ASH, and in the coming years. Because what we know about monoclonal antibodies from many other clinical trials and many other clinical settings is that they seem to be additive to pretty much any other therapy that is available. So, I think what we are going to see is the addition of monoclonal antibodies to induction therapy, to consolidation therapy, and to maintenance therapy, and I think understanding which drug may be better suited for each of these different phases of treatment will depend on the clinical data. So far, we have just a few small trials. There is emerging data on randomized phase 3s, both with elotuzumab and daratumumab, that is coming in an induction therapy setting in combination with bortezomib and in combination with lenalidomide in larger phase 3 trials, and these will be critical to better answering those questions. Thank you for your attention and please tune into ManagingMyeloma.com for additional FAQs.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Author
Are there certain agents which can be selected for treatment which may lessen immunosuppression?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
Will clinical trials continue to enroll during this time?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
What education or instruction are you providing to your patients with myeloma who are already immunocompromised?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
How are you managing care delivery during the COVID-19 pandemic?
Sagar Lonial, MD, FACP
FAQ Library published on May 20, 2020
Practice-changing trials to watch for in 2018
Sagar Lonial, MD, FACP
FAQ Library published on January 24, 2018
A key educational message from ASH 2017
Sagar Lonial, MD, FACP
FAQ Library published on January 12, 2018
Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?
Sagar Lonial, MD, FACP
FAQ Library published on October 11, 2017
How will the new IMWG definition of active multiple myeloma impact clinical practice?
Sagar Lonial, MD, FACP
FAQ Library published on August 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD, FACP
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on June 15, 2016